PAR 1.96% 25.0¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

  1. 52 Posts.
    lightbulb Created with Sketch. 4
    Yeah really a nothingburger of a quarterly, spend not a blow out so hopefully the market anxiety dies down a bit.

    Understandably they can’t disclose much about ongoing deals but damn it would be nice to hear some positive news on that front.

    Optimistic for this quarter, I have an itch the FDA might come back sooner than thought, seems fairly open shut, just my 2c dyor
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.